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Abstract
Background: PKA is a ubiquitous, multi-subunit cellular kinase that regulates a number of different physiological
responses in response to cAMP, including metabolism, cell division, and cardiac function. Numerous studies have
implicated altered PKA signaling in cardiac dysfunction. Recently, it has been shown that mice lacking the catalytic
b subunit of PKA (PKA Cb) are protected from age-related problems such as weight gain and enlarged livers, and
we hypothesized that these mice might also be resistant to cardiomyopathy.
Findings: Angiotensin II (ang II) induced hypertension in both PKA Cb null mice and their WT littermates.
However, PKA Cb null mice were resistant to a number of ang II-induced, cardiopathological effects observed in
the WT mice, including hypertrophy, decreased diastolic performance, and enlarged left atria.
Conclusion: The Cb subunit of PKA plays an important role in angiotensin-induced cardiac dysfunction. The Cb
null mouse highlights the potential of the PKA Cb subunit as a pharmaceutical target for hypertrophic cardiac
disease.
Background
PKA is a ubiquitous cellular kinase that is involved in
regulating a vast number of different cellular processes.
Several studies have implicated altered PKA signaling in
cardiomyopathy [1,2]. For example, the onset of cardiac
hypertrophy is influenced by alterations in muscle-specific
A-kinase Anchoring Protein (mAKAP) signaling in myo-
cytes. AKAPs subcellularly localize and modulate interac-
tions between PKA and its downstream targets [3].
Deficiencies in the PKA pathway have also been linked
both to cardiomyopathy in humans due to reduced phos-
phorylation of downstream targets such as cardiac tropo-
nin I [4], and to preservation of cardiac function against
pressure overload in mice [5,6].
PKA is a tetrameric protein, consisting of two regula-
tory subunits and two catalytic subunits. Binding of
cAMP to the regulatory subunits releases the catalytic
subunits, which are then free to interact with and phos-
phorylate downstream targets. There are four isoforms
of the regulatory subunit (RIa, RIb, RIIa, RIIb) and
three types of catalytic subunits (Ca, Cb, Cg) [7,8]. C57/
BL6J male mice lacking the regulatory RIIb subunit have
been found to be resistant to a number of age-related
pathologies, including cardiac hypertrophy and decline
[9]. We are currently studying mice lacking the PKA
catalytic Cß subunit to establish whether they also enjoy
age-delaying benefits. To date, we know that when chal-
lenged with a high fat, high calorie diet, these mice
show robust obesity resistance, dramatic fat sparing
effects in the liver, and protection against insulin resis-
tance [10].
Cardiac hypertrophy is an increase in the mass of the
heart in response to and to compensate for an increased
workload. In the face of continued stress, hypertrophied
diastolic and eventually systolic properties of the left
ventricle become impaired, leading to decompensation
and heart failure [11]. Angiotensin (ang) II is the effec-
tor of the renin-angiotensin system (RAS), and increases
blood pressure by causing potent vasoconstriction
through stimulation of angiotensin receptors in the vas-
cular system [12]. We used ang II to administer a hyper-
tensive challenge to the hearts of PKA Cb null mice in
order to establish whether or not they were protected
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against pressure overload-induced cardiac hypertrophy
and dysfunction.
Methods
PKA Cb null mice lack expression of all PKA Cb iso-
forms [13]. Mice were backcrossed to congenicity on a
C57BL/6J background and genotypes were identified
with PCR, both as previously described [10]. Seven each
of 7 month-old, male PKA Cb null mice and their WT
littermates were surgically implanted with subcutaneous
osmotic minipumps (model 1004; Alzet, Cupertino CA),
to deliver a dosage of 0.7 mg/kg/day of Val5-angiotensin
II (H1750; Bachem, Torrance CA) for 28 days. Blood
pressures were measured before and after angiotensin
treatment using the Coda-6 VPR tail cuff system (Kent
Scientific, Torrington CT) [14,15] on conscious mice, as
previously described, [16]. Non-invasive echocardiogra-
phy and Doppler imaging were used before and 34 days
after implantation of the minipumps to assess left ven-
tricular mass, left atrial size, the velocity of the mitral
valve annulus, isovolumic contraction and relaxation
and ejection times, and the ratio of early to late diastolic
filling (Ea/Aa). At the end of the experiment, ang
II-treated mice were euthanized and their hearts
weighed and compared with heart weights from another
cohort of similarly aged, unchallenged mice. Probabil-
ities of difference between groups were calculated using
the Student’s T-test; P’s < 0.05 were considered to be
statistically significant and are included in figures. All
protocols were approved by the University of Washing-
ton Institutional Animal Care and Use Committee.
Results
PKA Cb null mice are resistant to angiotensin-induced
cardiac hypertrophy and dysfunction
Previous experiments have shown that insertion of
subcutaneous saline pumps into mice, using our method
does not produce any cardiovascular effects (data not
shown). Four weeks of treatment with pumps containing
angiotensin II caused a systolic and diastolic blood pres-
sure increase of 25 and 50%, and 35 and 36%, for WT
and PKA Cb null mice, respectively (figure 1). Signifi-
cant differences in blood pressure were not found
between genotypes, either before or after ang II treat-
ment. Echocardiography and Doppler imaging show
similar cardiac performance between unchallenged, 7
month-old PKA Cb null mice and their WT littermates
(data not shown); however, when challenged with angio-
tensin II, compared to WT, mutants were found to be
resistant to cardiac dysfunction in 4 of the 5 parameters
measured (figure 2). Mutants displayed only a 60%
increase in left ventricular mass index compared to over
100% in the WT. WT mice also showed significant
decreases in fractional shortening of the left vetricle,
compared to their mutant littermates which showed no
decreases at all. The left atrium of the WT hearts,
showed, on average, a significantly larger increase in size
in response to ang II, reflected by a 25% decrease in the
average aorta/left atrium ratio (AO/LA) compared to no
change in the mutants. The ratio of early to late diasto-
lic filling (Ea/Aa) decreased by over 40% in WT com-
pared to about 10% in mutants, indicating significantly
worse diastolic dysfunction. The only parameter equally
affected in both genotypes was mass performance index
(MPI). Results from echocardiography showing differ-
ences between genotypes in ang II-induced hypertrophy
were confirmed upon euthanization of the mice.
Unchallenged PKA Cb null and WT mice had similar
heart weights of about 0.15 g. After 28 days of ang II
treatment, however, the hearts of WT mice were 38%
larger, while PKA Cb null hearts showed a significantly
smaller increase of only about 17% (figure 3A). The dif-
ference in heart size between genotypes of ang II treated
mice was clearly visible (figure 3B).
Discussion
We show that disruption of the PKA catalytic subunit
Cb protects mice from angiotensin II-induced cardiac
hypertrophy and dysfunction. In this study, a low dosage
of angiotensin II (ang II) was used to effectively induce
hypertension in WT, C57BL/6J mice and their PKA Cb
null littermates. After being challenged for 4 weeks with
ang II, both genotypes showed a similar hypertensive
response. In spite of similar systolic and diastolic blood
pressure increases in response to ang II compared to
Figure 1 Angiotensin II causes hypertension in Cb null mice
and WT littermates. Blood pressure measurements from Cb null
mice and their WT littermates, pre and post treatment with
angiotensin II. Both genotypes showed similar systolic and diastolic
blood pressure before angiotensin treatment. Following 4 weeks of
treatment, both Cb null and WT mice showed similar and significant
increases in systolic and diastolic blood pressure. n = 7 mice per
genotype; error bars indicate standard deviations. Probabilities <
0.05 indicated on graph.
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WT, Cb null mutants displayed smaller hearts and
improved cardiac function in 4 of 5 echocardiographical
parameters measured including left ventricular mass
index, fractional shortening, ratio of early to late diasto-
lic filling, and ratio of aortic to left atrial diameter.
Only mass performance index showed no difference
between genotypes. The role that ang II plays in the
renin-angiotensin system (RAS) is known to be pivotal
in the regulation of blood pressure [17]. Resistance of
PKA Cb null mice to cardiac hypertrophy demonstrates
that PKA plays a role in the mediation of hypertension
and its myopathological effects, although what that role
is remains to be elucidated.
It has been known for some time that the b-adrenergic
(b-AR)/adenylyl cyclase/PKA pathway, which is central
to stimulating cardiac function, is dysfunctional in heart
failure [18]. That b-AR signaling is detrimental to cardiac
function is supported by clinical studies in humans show-
ing that blockade of b-AR receptors improves survival in
heart failure patients [19], and by studies on transgenic
mice, showing that chronic activation of the cAMP-PKA
pathway by cardiac-specific overexpression of b-AR, Gsa,
Figure 2 PKA Cb null mice are resistant to angiotensin II-induced cardiac hypertrophy and dysfunction. Echocardiography and Doppler
analyses of WT and PKA Cb null littermates, pre and post angiotensin treatment. 5 parameters of cardiac morphology and function were
measured: FS (fractional shortening of the left ventricle), Ea/Aa (ratio of early over late diastolic filling), AO/LA (ratio of the aortic diameter/left
atrial diameter), LVMI (left ventricular mass index, standardized to tibia length) and MPI (mass performance index). The hearts of angiotensin-
treated PKA Cb null mice were significantly superior to those of WT littermates, for 4 of the 5 parameters measured. n = 7 per genotype; error
bars represent standard deviations. Probabilities < 0.05 indicated on graph.
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and the a-catalytic subunit of PKA result in cardiomyo-
pathy [2,20]. Disruption of adenylyl cyclase 5, which was
shown to diminish cAMP-PKA signaling in the heart by
30-40%, was also shown to protect the murine heart from
pressure overload-induced decompensation, although it
did not affect the development of hypertrophy [5]. b-AR
signaling can be overstimulated by hypertension [21],
and PKA is known to instigate cardiac hypertrophy in
response to elevation of cAMP by b-adrenergic agonists
[22]. A reduction in the response of the b-AR pathway to
hypertension could be the reason for the protective car-
diac effects of the Cb null mutation. There are, however,
opposing studies that point to a protective role for the b-
AR/AC/PKA pathway in response to hemodynamic over-
load. In humans, PKA-dependent phosphorylation of car-
diac troponin I (TnI) has been found to be reduced in
dilated cardiomyopathy [4], supporting the idea that loss
of responsiveness of the b-AR pathway plays a role in
cardiomyopathy. This finding is also supported in mice:
overexpression of two types of adenylyl cyclase in the
heart result in improved cardiac function [23,24].
Another PKA mutant mouse model lacking the regula-
tory RIIb subunit of PKA [25,26], displays an obesity
resistant phenotype similar to the Cb null mutant [9],
and is thought to be sensitive to b-adrenergic activation
[27,28], an idea that is supported by their exaggerated
sensitization response to amphetamine [29]. Similarities
in other phenotypes between RIIb null and Cb null
mutants indicate that they may also share enhanced b-
AR signaling. It is unknown why in some cases, loss of b-
AR signaling seems protective to cardiac function, and in
other cases, the opposite seems to be true. The
Figure 3 Hearts from PKA Cb null mice are resistant to hypertrophic effects of angiotensin. A. Heart weights of WT and PKA Cb null
mice, before and after treatment with angiotensin II. Hearts of unchallenged mice showed similar weights regardless of genotype, but hearts of
WT mice after angiotensin II treatment were significantly larger that those of PKA Cb null littermates. Heart weights standardized to tibia length.
n = 7 per genotype; error bars represent standard deviations. Probabilities < 0.05 indicated on graph. B. Hearts of angiotensin II-treated WT mice
were visibly larger than those of Cb null littermates. Echocardiographical measurements of LVMI were confirmed both visually and by weighing
the hearts; the angiotensin II-treated WT heart on the left was found using echocardiography to have an LVMI of 4.07 while the challenged Cb
null heart on the right was found to have an LVMI of only 2.15.
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conflicting data does indicate that disruption of the dif-
ferent components of the b-AR pathway, and even differ-
ent components of the PKA enzyme itself, have different
consequences on cardiac performance. It is also unknown
if and how the b-AR pathway is affected in PKA Cb null
mice, but the idea that alterations in this pathway may be
in part responsible for the protective effects of the Cb
mutation on ang II-induced cardiomyopathy needs to be
taken into consideration.
Other potential roles for PKA in protection against
cardiac hypertrophy and dysfunction are numerous and
diverse. Cyclic AMP signaling regulates a vast number
of cellular processes, including cellular growth [30]. Spe-
cifically, activation of cAMP-PKA signaling has been
shown to inhibit smooth muscle proliferation [31]. Like
angiotensin II, cAMP/PKA transiently stimulates the
expression of immediate-early genes [32]. In addition,
PKA is known to regulate activity of some of the same
pathways both activated by ang II and linked to cardiac
hypertrophy; for example, PKA modulates ANF-
dependent cGMP accumulation in renal cells [33].
Hypertrophy of cardiomyocytes in response to hyperten-
sion is thought to compensate for wall stress, and is
characterized by an increase in cell size and enhanced
protein synthesis [34]. Stretching of cardiomyocytes in
response to haemodynamic overload is known to
increase protein synthesis by activating second messen-
gers such as Raf-1 kinase and extracellular signal-regu-
lated protein kinases (ERKs) through activation of
protein kinase C (PKC) [35]. Activation of PKA has
been shown to have a synergistic effect on PKC-induced
stimulation of Raf-1 and MAP kinases in rat cardiomyo-
cytes[36,37], and disruption of PKA Cb may reduce this
effect. Growth factors may also play a role. For example,
epidermal growth factor receptor (EGFR) phosphoryla-
tion is known to be involved in the development of
pressure overload-induced cardiac hypertrophy [38]. In
liver, disruption of Cb leads to a reduction in EGFR
levels [39], although this result still needs to be con-
firmed in the heart. Other downstream targets of PKA
in myocytes include the L-type Ca2+ channel in the sar-
colemma, the ryanodine receptor (RyR2), and phospho-
lamban in the sarcoplasmic reticulum (SR) [40,20].
There is substantial evidence that calcium signaling
pathways play a role in cardiac hypertrophy [41,42], sup-
ported by the finding that its development in rats, in the
presence of hypertension can be inhibited by blockade
of L-type calcium channels [43]. Finally, PKA has
recently been found to inhibit nuclear export of histone
deacetylase 5 (HDAC5), resulting in inhibited gene tran-
scription and attenuated phenylephrine and angiotensin
II-induced rat cardiomyocyte hypertrophy [44]. HDACs
play a role in the transcriptional regulation of myocyte
enhancer factor 2 (MEF2), a transcription factor that
activates many cardiac genes and is known to be
involved in the development of cardiac hypertrophy [45].
Conclusions
This study shows a clear role for the b catalytic subunit
of PKA in ang II-induced cardiomyopathy. Not only
does it illustrate the usefulness of the PKA Cb null
mouse for the study of the role of PKA signaling in
heart disease; it also highlights the potential of the PKA
Cb subunit as a pharmaeutical target in the treatment of
cardiac hypertrophy and dysfunction.
Acknowledgements
WCL and LCE were supported by Ellison Medical Foundation. KLB was
supported by the Nathan Shock Center (NIA). Blood pressure measurements
were obtained, in part, by the Seattle MMPC (U24 DK076126).
Authors’ contributions
WCL conceived the study. KLB performed the echocardiography and
Doppler analyses. LCE was responsible for the study’s design and
coordination, performed the statistical analyses of the data, and drafted the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 May 2010 Accepted: 16 November 2010
Published: 16 November 2010
References
1. Enns LC, Pettan-Brewer C, Ladiges WC: Protein kinase A is a target for
aging and the aging heart. Aging 2010, 2:238-243.
2. Lohse MJ, Engelhardt S: Protein kinase A transgenes: the many faces of
cAMP. Circ Res 2001, 89:938-940.
3. McConnachie G, Langeberg LK, Scott JD: AKAP signaling complexes:
getting to the heart of the matter. Trends Mol Med 2006, 12:317-323.
4. Zakhary DR, Moravec CS, Stewart RW, Bond M: Protein Kinase A (PKA)-
dependent Troponin-I phosphorylation and PKA regulatory subunits are
decreased in human dilated cardiomyopathy. Circ 1999, 99:505-5.
5. Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, Liu J, Vatner DE,
Sadoshima J, Vatner SF, Ishikawa Y: Disruption of type 5 adenylyl cyclase
gene preserves cardiac function against pressure overload. PNAS 2003,
100:9986-9990.
6. Okumura S, Kawabe J, Yatani A, Takagi G, Lee MC, Hong C, Liu J, Takagi I,
Sadoshima J, Vatner DE, Vantner SF, Ishikawa Y: Type 5 adenylyl cyclase
disruption alters not only sympathetic but also parasympathetic and
calcium-mediated cardiac regulation. Circ Res 2003, 93:364-374.
7. McKnight GS: Differential expression of mRNAs for protein kinase
inhibitor isoforms in mouse brain. Curr Opin Cell Biol 1991, 3:213-217.
8. Brandon EP, Idzerda RL, McKnight GS: PKA isoforms, neural pathways, and
behaviour: making the connection. Curr Opin Neurobiol 1997, 7:397-403.
9. Enns L, Morton J, Treuting P, Emond M, Wold N, McKnight GS,
Rabinovitch P, Ladiges W: Disruption of protein kinase A in mice
enhances healthy aging. PLoS ONE 2009, 4(6):e5963.
10. Enns LC, Morton JF, Mangalindan RS, McKnight GS, Schwartz MW,
Kaeberlein MR, Kennedy BK, Rabinovitch PS, Ladiges WC: Attenuation of
age-related metabolic dysfunction in mice with a targeted disruption of
the Cβ subunit of protein kinase A. J Gerontol A 2009, 64:1221-1231.
11. Shapiro LM, Sugden PH: Left ventricular hypertrophy. In Diseases of the
Heart. 2 edition. Edited by: Julian DG, Damm AJ, Fox KM, Hall RTC, Poole-
Wilson PA. London: Saunders; 1996.
12. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM:
Regulation of blood pressure by the type 1A anigotensin II receptor
gene. PNAS 1995, 92:3521-3525.
13. Howe DG, Wiley JC, McKnight GS: Molecular and behavioural effects of a
null mutation in all PKA Cβ isoforms. Mol Cell Neurosci 2002, 20:515-524.
Enns et al. BMC Research Notes 2010, 3:307
http://www.biomedcentral.com/1756-0500/3/307
Page 5 of 6
14. Whitesall SE, Hoff JB, Vollmer AP, D’Alecy LG: Comparison of simultaneous
measurement of mouse systolic arterial blood pressure by
radiotelemetry and tail-cuff methods. Am J Physiol Heart Circ Physiol 2004,
286:H2408-2415.
15. Feng M, Whitesall S, Zhang Y, Beibel M, D’Alecy L, DiPetrillo K: Validation of
volume-pressure recording tail-cuff blood pressure measurements. Am J
Hypertens 2008, 21:1288-1291.
16. Guo S, Kowalewska J, Wietecha TA, Iyoda M, Wang L, Yi K, Spencer M,
Banas M, Alexandrescu S, Hudkins KL, Alpers CE: Renin-angiotensin system
blockade is renoprotective in immune complex-mediated
glomerulonephritis. J Am Soc Nephrol 2008, 19:1168-1176.
17. Reid IA, Morris BJ, Ganong WJ: The renin-angiotensin system. Annu Rev
Physiol 1978, 40:377-410.
18. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K,
Billingham ME, Harrison DC, Stinson EB: Decreased catecholamine
sensitivity and β-adrenergic-receptor density in failing human hearts. N
Engl J Med 1982, 307:205-211.
19. Bristow MR: β-Adrenergic receptor blockade in chronic heart failure.
Circulation 2000, 101:558-569.
20. Antos CL, Frey H, Marx SO, Reiken S, Gaburjakova M, Richardson JA,
Marks AR, Olson EN: Dilated cardiomyopathy and sudden death resulting
from constitutive activation of protein kinase A. Circ Res 89:997-1004.
21. Park SJ, Choi DJ, Kim CW: Hypertensive left ventricular hypertrophy:
relation to beta-adrenergic receptor kinase-1 (betaARK1) in peripheral
lymphocytes. J Hypertens 2004, 22:1025-1032.
22. Rockman HA, Koch WJ, Lefkowitz RJ: Seven-transmembrane-spanning
receptors and heart function. Nature 2002, 415:206-212.
23. Lipskaia L, Defer N, Esposito G, Hajar I, Garel MC, Rockman HA, Hanoune J:
Enhanced cardiac function in transgenic mice expressing a Ca2
+-stimulated adenylyl cyclase. Cir Res 2000, 86:795-801.
24. Gao MH, Lai NC, Roth DM, Zhou JY, Zhu J, Dalton N, Anzai T, Hammond K:
Adenylyl cycylase increases responsiveness to catecholamine stimulation
in transgenic mice. Circ 1999, 99:1618-1622.
25. Cummings DE, Brandon EP, Planas JV, Motamed K, Idzerda RL, McKnight GS:
Genetically lean mice result from targeted disruption of the RIIß subunit
of protein kinase A. Nature 1996, 382:622-626.
26. Amieux PS, Cummings DE, Motamed K, Brandon EP, Wailes LA, Le K,
Idzerda RL, McKnight GS: Compensatory regulation of RIα protein levels
in protein kinase A mutant mice. J Biol Chem 1997, 272:3993-3998.
27. McKnight GS, Cummings DE, Amieux PS, Sikorski MA, Brandon EP, Planas JV,
Motamed K, Idzerda RL: Cyclic AMP, PKA, and the physiological
regulation of adiposity. Recent Prog Hormone Res 1998, 53:139-161.
28. Montovani G, Bondioni S, Alberti L, Gilardini L, Invitti C, Corbetta S,
Zappa MA, Ferrero S, Lania AG, Bosari S, Beck-Peccoz P, Spada A:
Decreased R2B expression and activity in adipocytes from obese
subjects. Diabetes 2009, 58:620-626.
29. Brandon EP, Logue SF, Adams MR, Qi M, Sullivan SP, Matsumoto AM,
Dorsa DM, Wehner JM, McKnight GS, Idzerda RL: Defective motor
behaviour and neural gene expression in RIIβ-protein kinase A mutant
mice. J Neurosci 1998, 18:3639-3649.
30. Indolfi C, Chiariello M, Avvedimento EV: Selective gene therapy for
proliferative disorders: Sense and antisense. Nature Med 1996, 2:634-635.
31. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciulo A,
Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, Condorelli G,
Chiariello M: Activation of cAMP-PKA signaling in vivo inhibits smooth
muscle cell proliferation induced by vascular injury. Nature Med 1997,
3:775-779.
32. Chen X, Dai JC, Greenfielde EM: Termination of immediate-early gene
expression after stimulation by parathyroid hormone or isoproterenol.
Am J Physiol Cell Physiol 2002, 283:C1432-C1440.
33. Ledoux S, Dussaule C, Chatziantoniou C, Ardaillou N, Vandermeersch S,
Ardaillou R: Protein kinase A activity modulates natriuretic peptide-
dependent cGMP accumulation in renal cells. Am J Physiol Cell Physiol
1997, 272:C82-C89.
34. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WPN: Prognostic
implications of echocardiographically determined left ventricular mass
in the Framingham Heart Study. Engl J Med 1990, 322:1561-1566.
35. Yamazaki T, Komuro I, Yazaki Y: Signalling pathways for cardiac
hypertrophy. Cell Signal 1998, 10:693-698.
36. Yamazaki T, Komuro I, Zou Y, Kudoh S, Mizuno T, Hiroi Y, Shiojima I,
Takano H, Kinugawa K, Kohmoto O, Takahashi T, Yazaki Y: Protein kinase A
and protein kinase C synergistically activate the Raf-1 kinase/mitogen-
activated protein kinase cascade in neonatal rat cardiomyocytes. J Mol
Cell Cardiol 1997, 29:2491-2501.
37. Yamazaki T, Komuro I, Zou Y, Kudoh S, Shiojima I, Hiroi Y, Mizuno T,
Aikawa R, Takano H, Yazaki Y: Norepinephrine induces the raf-1 kinase/
mitogen-activated protein kinase cascade through both α1- and β-
adrenoceptors. Circ 1998, 95:1260-1268.
38. Liao Y, Asakura M, Takashima S, Kato H, Asano Y, Shintani Y, Minamino T,
Tomoike H, Hori M, Kitakaze M: Amlodipine ameliorates myocardial
hypertrophy by inhibiting EGFR phosphorylation. Biochem Biophys Res
Com 2005, 327:1083-1087.
39. Oksvold MP, Funderud A, Kvissel AK, Skarpen E, Henanger H, Huitfeldt HS,
Skålhegg BS, Ørstavik S: Epidermal growth factor receptor levels are
reduced in mice with targeted disruption of the protein kinase A
catalytic subunit. BMC Cell Biol 2008, 9:16.
40. Kass RS, Moss AJ: Long QT syndrome: novel insights into the
mechanisms of cardiac arrhythmias. J Clin Invest 2003, 112:810-815.
41. Passier P, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek Pk,
Richardson JA, Grant SR, Olson EN: CaM kinase signaling induces cardiac
hypertrophy and activates the MEF2 transcription factor in vivo. J Clin
Invest 2000, 105:1395-1406.
42. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME,
Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR: Chronic
phospholamban-sarcoplasmic reticulum calcium ATPase interaction is
the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999,
99:313-322.
43. Zou Y, Yamazaki T, Nakagawa K, Yamada H, Iriguchi N, Toko H, Takano H,
Akazawa H, Nagai R, Komuro I: Continuous blockade of L-type Ca2+
channels suppresses activation of calcineurin and development of
cardiac hypertrophy in spontaneously hypertensive rats. Hypertens Res
2002, 25:117-124.
44. Ha CH, Kim JY, Zhao J, Wang W, Juhn BS, Wong C, Jin ZG: PKA
phosphorylates histone deacetylase 5 and prevents its nuclear export,
leading to the inhibition of gene transcription and cardiomyocyte
hypertrophy. PNAS 2010, 107:15467-15472.
45. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN: Histone
deacetylases 5 and 9 govern responsiveness of the heart to a subset of
stress signals and play redundant roles in heart development. Mol Cell
Biol 2004, 24:8467-8476.
doi:10.1186/1756-0500-3-307
Cite this article as: Enns et al.: Mice lacking the Cb subunit of PKA are
resistant to angiotensin II-induced cardiac hypertrophy and dysfunction.
BMC Research Notes 2010 3:307.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Enns et al. BMC Research Notes 2010, 3:307
http://www.biomedcentral.com/1756-0500/3/307
Page 6 of 6
